| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $750K | — | +892.7% |
| SG&A Expense | $1.5M | — | -6.6% |
| Operating Income | -$2.3M | — | -32.9% |
| Net Income | -$2.2M | — | -30.1% |
| EPS (Basic) | -$4.18 | — | -305.8% |
| EPS (Diluted) | -$4.18 | — | -305.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.8M | -27.0% | +334.9% |
| Current Assets | $8.4M | -23.9% | +262.6% |
| Total Assets | $8.4M | -23.8% | +260.1% |
| Current Liabilities | $4.5M | -12.0% | — |
| Total Liabilities | $4.5M | -12.0% | +99.6% |
| Stockholders' Equity | $3.9M | -34.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.9M | — | -144.5% |
| Financing Cash Flow | $0 | — | -100.0% |
| +6167.4% |